Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Andrew King appointed President, Research & Development effective April 18, 2026.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Andrew King appointed President, Research & Development effective April 18, 2026
- Expanded leadership role from Chief Scientific Officer and Head of Research & Development
- No compensation changes, limiting immediate incremental expense impact
- Appointment signals continued internal leadership for Jade’s research pipeline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.